These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 30002107

  • 1. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
    Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M.
    J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
    [Abstract] [Full Text] [Related]

  • 2. Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.
    Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D.
    J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N.
    Grzmil M, Qin Y, Schleuniger C, Frank S, Imobersteg S, Blanc A, Spillmann M, Berger P, Schibli R, Behe M.
    Theranostics; 2020 Apr; 10(24):10861-10873. PubMed ID: 33042258
    [Abstract] [Full Text] [Related]

  • 4. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
    Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, Virgolini I, von Guggenberg E.
    J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
    [Abstract] [Full Text] [Related]

  • 5. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E.
    Theranostics; 2018 Jul; 8(11):2896-2908. PubMed ID: 29896292
    [Abstract] [Full Text] [Related]

  • 6. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
    Nock BA, Maina T, Krenning EP, de Jong M.
    J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
    [Abstract] [Full Text] [Related]

  • 7. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    Günther T, Holzleitner N, Viering O, Beck R, Wienand G, Dierks A, Pfob CH, Bundschuh RA, Kircher M, Lapa C, Wester HJ.
    J Nucl Med; 2024 Jan 02; 65(1):33-39. PubMed ID: 37945383
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [177Lu]Lu-PP-F11N.
    Grzmil M, Imobersteg S, Blanc A, Frank S, Schibli R, Béhé MP.
    Pharmaceutics; 2021 Dec 15; 13(12):. PubMed ID: 34959437
    [Abstract] [Full Text] [Related]

  • 9. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.
    Kaloudi A, Nock BA, Lymperis E, Sallegger W, Krenning EP, de Jong M, Maina T.
    Nucl Med Biol; 2015 Nov 15; 42(11):824-32. PubMed ID: 26300210
    [Abstract] [Full Text] [Related]

  • 10. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
    Hörmann AA, Klingler M, Rezaeianpour M, Hörmann N, Gust R, Shahhosseini S, Guggenberg EV.
    Molecules; 2020 Oct 08; 25(19):. PubMed ID: 33049999
    [Abstract] [Full Text] [Related]

  • 11.
    Chopra A.
    ; 2004 Oct 08. PubMed ID: 22787691
    [Abstract] [Full Text] [Related]

  • 12.
    Chopra A.
    ; 2004 Oct 08. PubMed ID: 22855967
    [Abstract] [Full Text] [Related]

  • 13. Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin 177Lu-PP-F11N.
    Grob NM, Schibli R, Béhé M, Mindt TL.
    Cancers (Basel); 2021 May 27; 13(11):. PubMed ID: 34071914
    [Abstract] [Full Text] [Related]

  • 14. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon.
    Kaloudi A, Nock BA, Lymperis E, Krenning EP, de Jong M, Maina T.
    Cancer Biother Radiopharm; 2016 Feb 27; 31(1):20-8. PubMed ID: 26844849
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
    Roosenburg S, Laverman P, Joosten L, Eek A, Rutjes FP, van Delft FL, Boerman OC.
    Mol Imaging; 2012 Feb 27; 11(5):401-7. PubMed ID: 22954184
    [Abstract] [Full Text] [Related]

  • 16. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
    Zavvar TS, Hörmann AA, Klingler M, Summer D, Rangger C, Desrues L, Castel H, Gandolfo P, von Guggenberg E.
    Pharmaceuticals (Basel); 2023 Feb 13; 16(2):. PubMed ID: 37052226
    [Abstract] [Full Text] [Related]

  • 17. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
    Tornesello AL, Aurilio M, Accardo A, Tarallo L, Barbieri A, Arra C, Tesauro D, Morelli G, Aloj L.
    J Pept Sci; 2011 May 13; 17(5):405-12. PubMed ID: 21351319
    [Abstract] [Full Text] [Related]

  • 18. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
    Breeman WA, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, Maina T, Nock BA, Erion JL, Mäcke HR, Krenning EP.
    Nucl Med Biol; 2008 Nov 13; 35(8):839-49. PubMed ID: 19026945
    [Abstract] [Full Text] [Related]

  • 19.
    Chopra A.
    ; 2004 Nov 13. PubMed ID: 23390667
    [Abstract] [Full Text] [Related]

  • 20. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
    Roosenburg S, Laverman P, Joosten L, Cooper MS, Kolenc-Peitl PK, Foster JM, Hudson C, Leyton J, Burnet J, Oyen WJ, Blower PJ, Mather SJ, Boerman OC, Sosabowski JK.
    Mol Pharm; 2014 Nov 03; 11(11):3930-7. PubMed ID: 24992368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.